Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2025-08-01

Summary

To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension compared with the placebo in the treatment of Chinese patients with COPD.

• Phase: PHASE2

Details

• Lead Sponsor: Haisco Pharmaceutical Group Co., Ltd.